title: Selecting the best haploidentical donor.
abstract: The substantial evidence of the safety of human leukocyte antigen (HLA)-haploidentical (haplo) blood or marrow transplantation (BMT) has led to its increasing utilization. When prioritizing HLA-matched grafts, patients frequently have few or no donors from whom to choose. However, a given patient may have multiple suitable haplo donors. Therefore factors other than HLA-match become critical for selecting the best donor. We recommend a donor selection algorithm based on the donor-specific antibodies, ABO match, donor age, donor sex, and cytomegalovirus (CMV) serostatus match. Despite provocative initial evidence, further studies are warranted to determine whether there is any benefit to selecting a haplo donor based on the number of HLA-mismatches, natural killer cell alloreactivity, or the presence of non-inherited maternal HLA antigens.
authors: Johns Hopkins University, Baltimore, MD. Electronic address: smccurd2@jhmi.edu.
authors: Shannon R
authors: SR
authors: McCurdy
authors: Johns Hopkins University, Baltimore, MD.
authors: Ephraim J
authors: EJ
authors: Fuchs
mesh_terms: D000017:ABO Blood-Group System; D006680:HLA Antigens / Q000276:immunology; D006238:Haploidy; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D014019:Tissue Donors
chemical_list: D000017:ABO Blood-Group System; D006680:HLA Antigens
keywords: Donor Selection; Haploidentical; Post-transplant cyclophosphamide